Concepedia

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual, Cristina Hernándo, Montserrat Muñoz-Mateu, Laia Paré, Blanca González‐Farré, Pedro L. Fernández, Patricia Galván, Núria Chic,

The Lancet Oncology · 2019 · 201 citations · 23 references

DOI

Concepts

References

23

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang et al. · Journal of Clinical Oncology · 2009 · 4.9K citations · Full text

, , +16

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

C. J. Clopper, E. S. Pearson · Biometrika · 1934 · 4.8K citations

, , +16

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

, , +17

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Joseph A. Sparano, Robert J. Gray, Della Makower et al. · New England Journal of Medicine · 2018 · 2.4K citations · Full text

, , +17

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text

, , +17